Sign in
CompletedNo phase

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)

Key facts

Who runs it
BioMarin Pharmaceutical
Where
Ann Arbor, Boston, Chicago, Decatur, Durham, Honolulu, Houston, Iowa City, Las Vegas, Little Rock, Los Angeles, Louisville, Miami, Milwaukee, Minneapolis, Morristown, New York, Norfolk, Orange, Philadelphia, Phoenix, Pittsburgh, Seattle, Washington D.C., and Wilmington, United StatesSee the 26 sitesAlso in 16 other countries, 53 sites
Trial code
Status
Completed
People taking part
418 people enrolled
Started
Sept 2014
Ended
21 Feb 2024
Type of study
Observational
Treatments tested
  • Vimizim® (elosulfase alfa)
Record updated
5 March 2024

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients eligible to participate in this Registry must meet all of the following criteria:
  • Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine 6-sulfatase (GALNS) enzymatic test or by a diagnostic molecular test
  • Willing and able to provide written, signed informed consent, or, in the case of patients age < 18 years, provide written assent (if required) and written informed consent, signed by a legally authorized representative after the nature of the Registry has been explained and prior to performance of any Registry-related procedures
  • Willing to undergo assessments to establish baseline data or permit Investigator to enter assessment data recorded prior to Registry entry if available in the patient's medical records. Entry assessments may include: demographics, medical history, urinary keratan sulfate level, urinary protein level, immunogenicity testing, vital signs, physical examination, and height and weight; Patients eligible to participate in the Registry Substudy for MOR-005 must meet all of the following criteria:
  • Must have completed the MOR-005 clinical trial
  • Willing and able to provide written, signed informed consent, or, in the case of patients age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the Registry Substudy has been explained and prior to any Registry-related Substudy procedures
  • Willing to permit Investigator to enter assessment data recorded prior to Registry
  • Substudy entry if available in the patient's medical records; Patients eligible to participate in this Registry Substudy for MOR-007 must meet all of the following criteria:
  • Must have completed the MOR-007 clinical trial
  • Willing and able to provide written, signed informed consent, or in the case of patients age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the Registry Substudy has been explained, and prior to any Registry-related Substudy procedures
  • Willing to permit Investigator to enter assessment data recorded prior to Registry Substudy entry if available in the patient's medical records

Who cannot take part

  • Patients who meet the following exclusion criterion will not be eligible to participate in the Registry or Registry Substudies:
  • Patients currently participating in a BMN 110 (elosulfase alfa) clinical trial

Where in United States

Also in 16 other countries, 53 sites

  • University of MichiganAnn Arbor, United States
  • Children's Hospital of BostonBoston, United States
  • Ann & Robert H. Lurie Children's HospitalChicago, United States
  • Emory UniversityDecatur, United States
  • Duke University Medical CenterDurham, United States
  • Kapiolani Medical Center for Women and ChildrenHonolulu, United States
  • UTHealth McGovern Medical SchoolHouston, United States
  • University of IowaIowa City, United States
  • Children's Specialty Center of NevadaLas Vegas, United States
  • Arkansas Children's HospitalLittle Rock, United States
  • Children's Hospital of Los AngelesLos Angeles, United States
  • University of Southern CaliforniaLos Angeles, United States
  • University of Louisville Research Foundation Inc./Kosair Charities Pediatric Clinical Research UnitLouisville, United States
  • Miami Children's HospitalMiami, United States
  • Children's Hospital of WisconsinMilwaukee, United States
  • Children's Hospitals and Clinics of MinnesotaMinneapolis, United States
  • Atlantic Health SystemMorristown, United States
  • NYU-Langone Medical Center School of MedicineNew York, United States
  • Children's Hospital of The King's DaughtersNorfolk, United States
  • Children's Hospital of Orange CountyOrange, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Phoenix Children s HospitalPhoenix, United States
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United States
  • Seattle Children's HospitalSeattle, United States
  • Children's National Health SystemWashington D.C., United States
  • A.I. duPont Hospital for ChildrenWilmington, United States

About the trial

What the trial wants to find out

The objectives of this program are: to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA; to evaluate the long-term effectiveness and safety of Vimizim®, including, but not limited to, the occurrence of serious hypersensitivity reactions, anaphylaxis, and changes in antibody status; to help the medical community with the development of recommendations for monitoring MPS IVA patients and reports on patient outcomes to optimize patient care; to collect data on other treatment paradigms, and evaluate the prevalences of their use and their effectiveness; to characterize the effects and safety of Vimizim treatment 5 years from enrollment in the Registry for patients under 5 years of age; to monitor pregnancy exposure, including maternal, neonatal, and infant outcomes; and to monitor patients who have completed the MOR-005 and MOR-007 clinical trials. These patients will be encouraged to enroll in the applicable Registry Substudy and will be monitored using the MOR-005 and MOR-007 assessment schedules, respectively.

Treatments tested

  • Vimizim® (elosulfase alfa)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 March 2024